DNAtix, the Genetics Blockchain Company, Introduces Complete Genome Sequencing Pilot and Announces Token Sale
Anonymous DNA Testing, Transfer, Storage with Total Control of Personal Data
AMSTERDAM, Netherlands, June 27, 2018 (GLOBE NEWSWIRE) -- Digital DNAtix Ltd., the genetics blockchain company, today announced the pilot of a breakthrough blockchain-based infrastructure and ecosystem for anonymous genetic testing, services and research. DNAtix is the first company to successfully transfer a genetic sequence over the Ethereum Blockchain. The DNAtix genetics ecosystem links individual users in the search of health solutions, or answers to ancestral questions, with products and services that fit their needs. DNAtix is also developing a dedicated Token - the DNATIX token - that will be integrated into the use of its DNAtix genetic platform.
"DNAtix is solving the privacy issue once and for all for testing highly sensitive DNA data with the first infrastructure blockchain ecosystem solution for anonymous genetic services," said Ofer A. Lidsky the CEO & CTO of the DNAtix. "Consumers, healthcare institutions, research centers, clinics, genetic counselors and others interested in using, testing, or gathering DNA data can now connect, work together for better health solutions and feel confident in sharing their genetic information."
Anyone can anonymously upload partial and/or full genome sequences onto the DNAtix platform; contributors own their genomic data and use it to make informed decisions.
Technology Breakthrough: An entire genetics ecosystem on the blockchain
Opening the door for advancements in research, new treatments, and cutting-edge personalized and preventive medicine, DNAtix's D2C platform provides full genome testing and access to services and solutions on the Blockchain and allows researchers to use anonymous DNA, stored on the DNAtix infrastructure, to create tests, do research and design new treatments.
In order to better leverage the emerging infrastructure and potential of blockchain genetic storage, DNAtix has developed and freely releases its compression algorithm for the mutual betterment of the field; Thus far, DNA storage efficiency has been increased by 300%.
GitHub repository: https://github.com/DNAtix/DNAtix-DNA-Compression-Tool
The DNATIX Token
DNAtix is in the private sale stage of its token to fund the delivery of anonymous genetic services at an affordable price point. The DNAtix token has smart contracts built into it enabling -for the first time- the anonymous and secure analysis, transfer, and storage of DNA sequences. The DNAtix wallet will facilitate anonymous payment for a wide range of genetic services. For more information and purchase instructions about DNAtix token sale, email: email@example.com.
SPEAKING: DNAtix AT BLOCKCHAIN EXPO EUROPE
Ofer A. Lidsky will be presenting twice at Blockchain Expo Europe:
|· Track:||Developing Blockchain Applications|
|· Day/Time:||Day 1 (27 June) 14:40 - 14:50|
|· Title:||Introducing new developments 2 (When Blockchain Meets Genetics)|
|· Track:||Blockchain Technologies|
|· Day/Time:||Day 2 (28 June) 09:40 - 10:20|
|· Keynote Panel:||What does the future hold for Blockchain technology - where do we think we will be in 2030?|
More information: https://blockchain-expo.com/europe/speaker/senior-representative-dnatix/
DNAtix, a cutting-edge genetics and blockchain company, is building the infrastructure for the world's genetic blockchain ecosystem where researchers, hospitals, developers, clinicians and others will develop next generation, decentralized genetics applications and health management solutions. DNAtix is also delivering a direct-to-consumer platform that offers anonymous and encrypted genome sequencing and genetic services, including digitized DNA analysis, storage and transfer. The DNAtix genetics ecosystem is a place where consumers and the industry can meet to share genetic data in a more transparent, accessible, applicable and secured manner. DNAtix is developing the future ecosystem for Genetics which is Blockchain based and includes cutting edge new innovative ideas and technologies. With a first successful proof of concept already completed for transferring a DNA sequence over the Ethereum blockchain DNAtix is leading the world of Genetic blockchain. www.dnatix.com
A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9f9e2aca-e48d-4d99-a20f-860e3995878b
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DNAtix via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Service Providers Speed Deployment, Reduce Costs with Patton Cloud Edge Orchestration Service20.9.2018 22:16 | Pressemelding
Now, Telecom and UCaaS service providers can easily provision, manage, monitor, secure, alert, troubleshoot, analyze, and optimize services on the customer premise GAITHERSBURG, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Patton Electronics—US-manufacturer of UC, cloud, and IoT-enabling solutions for carrier, enterprise, and industrial networks—has launched the new Patton Cloud service for carriers and service providers that deliver All-IP and hybrid voice-and-data services to business subscribers. Patton Cloud delivers a low-cost, easy-to-use, web-based edge-orchestration service that delivers a superior user experience. It offers remote touchless provisioning, monitoring, and troubleshooting—as well as security and alerting tools that reduce service turn-up costs, trouble tickets, and subscriber attrition. The Patton Cloud service offers quality-control mechanisms including pro-active monitoring and troubleshooting—combined with feature-license distribution pools for managing value-added
Inspirata Promotes Top Executives to Expanded Roles in Digital Pathology20.9.2018 21:12 | Pressemelding
Inspirata Founder and Executive Vice President, Mark Lloyd, is taking on an expanded role overseeing product management, and Inspirata Senior Vice President, Andrew Chomos, has been appointed to General Manager, Digital Pathology, overseeing the Center of Excellence in Pittsburgh along with all North America sales and customer support efforts. Tampa, FL, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that two of its executives have taken on expanded roles in the company. The two are Inspirata Executive Vice President and Founder, Mark Lloyd, and Senior Vice President and General Manager, Digital Pathology, Andrew Chomos. Dr. Lloyd has accepted the expansion of his role to include product management for Digital Pathology. He is former cancer researcher at both Lombardi Cancer and Moffitt Cancer Center and is Inspirata’s foremost subject matter expert and thought leader on digital pathology and image
Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections20.9.2018 19:08 | Pressemelding
– Broad Product Label for Treatment of Complicated Intra-Abdominal Infections – – Phased Commercial Launch Expected in the First Half of 2019 – WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that the European Commission (EC) has adopted the Decision granting marketing authorisation for XERAVA (eravacycline) for injection for the treatment of complicated intra-abdominal infections (cIAI) in adults in the European Union. In clinical trials, XERAVA was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem. “The European approval of XERAVA, right after our recently announced FDA approval, marks our second significant regulatory approval within one month
UPDATE— Taconic Biosciences Becomes the First Animal Model Provider on General Services Administration Contract Schedule20.9.2018 18:07 | Pressemelding
RENSSELAER, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces a new relationship with Government Scientific Source (GSS). GSS is a leading dedicated distributor of laboratory equipment to federal, state, and local governments on contract with the GSA (General Services Administration). By having Taconic’s products available via GSS, they can now be accessed by all federal agencies, including but not limited to the National Institutes of Health and the Department of Defense. Taconic is the only animal model provider affiliated with GSS and the only animal model provider available on GSA Contract. “An important component of providing customers with the best animal model solutions is access to key resources. Through this exciting new relationship with GSS, Taconic can now easily connect with scientists doing some of the most valuable research in the world and provide them with high quality sol
Digital Transformation is Not a One-Off — It’s About the Digital Journey20.9.2018 17:44 | Pressemelding
SoftServe study confirms four digital journey states with 71 percent of enterprises reporting early stages of adoption AUSTIN, Texas, Sept. 20, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, today released the results of its market research study that examines how enterprises are responding to the digital economy. The research found that 71 percent of the respondents in the United States and the European Union are in the early stages—Reveal and Transform—of four unique states across the Enterprise Digital Journey. For an in-depth analysis and the full results, read The Enterprise Digital Journey white paper. With fierce competition in today’s global landscape, leveraging cutting-edge technology and deploying new business models is not a one-off pursuit, but rather a continuous process of iteration and refinement. Companies should stop referring to Digital Transformation and instead plan for a continuous Digital Journey. “The term Digital Transfo
Anomali Announces Major Expansion of Threat Platform Partner Ecosystem20.9.2018 16:00 | Pressemelding
New Developer SDKs enable partners to integrate solutions with Anomali Threat Platform NATIONAL HARBOR, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Anomali today announced at the Detect Conference 2018 the expansion of the partner ecosystem with the launch of a suite of partner developer resources. The new tools enable easier and faster integration with the Anomali Threat Platform and APP Store, allowing clients immediate access to partner content, integrations and analytics. The partner program expansion includes the launch of a suite of software development kits (SDKs). The SDKs address three critical integration areas: Threat Intelligence Feeds SDK: integrate proprietary threat intelligence feeds and make these accessible via the APP Store Integration SDK: integrate threat intelligence from the Anomali Threat Platform into third party products and solutions Enrichment SDK: integrate 3rd party threat analysis and data enrichments into the Anomali Threat Platform “Organizations need a com
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom